Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital
Authors:
- María Jesús Pérez-GrandaMPMaría Jesús Pérez-Granda
- Pilar CatalánPCPilar Catalán
- Patricia MuñozPMPatricia Muñoz
- Teresa AldámizTATeresa Aldámiz
- Juan Camilo BarriosJBJuan Camilo Barrios
- Carlos RamírezCRCarlos Ramírez
- Rita García-MartínezRGRita García-Martínez
- María Victoria VillalbaMVMaría Victoria Villalba
- Luis PuenteLPLuis Puente
- Emilio BouzaEBEmilio Bouza
Open Access
- 22 November 2022
- journal article
- research article
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 36 (1) , 45-51
Abstract
Purpose. To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital. Methods. Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test. Results. We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis. Conclusion. CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.Keywords
This publication has 19 references indexed in Scilit:
- “The ancient and the new”: is there an interaction between cytomegalovirus and SARS-CoV-2 infection?Immunity & Ageing, 2020
- Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysisAnnals of Translational Medicine, 2020
- Current Understanding of Cytomegalovirus Reactivation in Critical IllnessThe Journal of Infectious Diseases, 2020
- Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the EvidenceThe Journal of Infectious Diseases, 2020
- Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and RecipientsTransplantation and Cellular Therapy, 2018
- Cytomegalovirus: Shape-Shifting the Immune SystemThe Journal of Immunology, 2018
- Cytomegalovirus Infection in Patients with Sepsis Due to Bloodstream Infections: Lower Risk and Better Outcomes in New versus Already Hospitalised Intensive Care Unit AdmissionsAnaesthesia and Intensive Care, 2016
- Cytomegalovirus reactivation in ICU patientsIntensive Care Medicine, 2015
- A Prospective Monitoring Study of Cytomegalovirus Infection in Non-Immunosuppressed Critical Heart Surgery PatientsPLOS ONE, 2015
- Increased mortality in long-term intensive care patients with active cytomegalovirus infection*Critical Care Medicine, 2008